Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Revolution Medicines, Inc.

Market Cap 31.57B 27.34B 25.16B 23.66B 44.04B 3,016B 44.71B 298B 116B 1,455B 119B 116B 5,054B P/E ratio 2026 *
-18.6x
P/E ratio 2027 * -26.3x
Enterprise value 28.25B 24.46B 22.51B 21.17B 39.4B 2,699B 40B 266B 104B 1,302B 106B 104B 4,522B EV / Sales 2026 *
288x
EV / Sales 2027 * 34.6x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Revolution Medicines, Inc.

1 day+2.36%
1 week-9.28%
Current month-5.71%
1 month+4.71%
3 months+50.90%
6 months+85.47%
Current year+86.43%
1 week 147.41
Extreme 147.41
159.34
1 month 141
Extreme 141
166.5
Current year 76.28
Extreme 76.28
166.5
1 year 34
Extreme 34
166.5
3 years 15.44
Extreme 15.4401
166.5
5 years 14.08
Extreme 14.08
166.5
10 years 14.08
Extreme 14.08
166.5
Manager TitleAgeSince
Chief Executive Officer 64 2014-10-31
Director of Finance/CFO 49 2018-09-30
Chief Tech/Sci/R&D Officer - 2024-06-30
Director TitleAgeSince
Chairman 64 2019-12-31
Director/Board Member 68 2015-02-28
Director/Board Member 54 2014-10-31
Date Insider Type Main position Quantity % Market Cap.
05-25Fiscal year

See Remarks

9,363 0.0044%
04-26Fiscal year

See Remarks

9,360 0.0047%
04-14Fiscal year

Chief Executive Officer

360,000 0.1817%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-9.28%+261.38%+497.79% 31.57B
+0.66%-1.07%-14.83%-12.74% 43.01B
+0.13%-1.68%+20.59%-10.91% 30.66B
+0.26%-3.18%+5.84%+24.76% 30.11B
-7.00%-12.69%+6.72%+8.66% 22.55B
-0.06%+5.71%+10.76%+8.39% 13.16B
-2.20%-5.95% - - 12.78B
+0.80%+1.42%+54.44%+106.55% 13.08B
-1.26%-2.44%+108.39%+76.57% 12.15B
+1.87%+10.29%+9.44%-32.36% 11.66B
Average -0.44%-2.00%+51.41%+74.08% 22.07B
Weighted average by Cap. -0.25%-3.12%+52.19%+85.75%

Financials

2026 *2027 *
Net sales 97.96M 84.83M 78.08M 73.43M 137M 9.36B 139M 923M 360M 4.52B 368M 360M 15.68B 830M 719M 662M 622M 1.16B 79.33B 1.18B 7.82B 3.05B 38.28B 3.12B 3.05B 133B
Net income -1.65B -1.43B -1.31B -1.23B -2.3B -157B -2.33B -15.53B -6.05B -75.96B -6.19B -6.05B -264B -1.12B -973M -895M -842M -1.57B -107B -1.59B -10.59B -4.13B -51.79B -4.22B -4.13B -180B
Net Debt -3.32B -2.88B -2.65B -2.49B -4.64B -318B -4.71B -31.32B -12.21B -153B -12.48B -12.21B -532B -2.88B -2.49B -2.29B -2.16B -4.02B -275B -4.08B -27.13B -10.58B -133B -10.81B -10.57B -461B
Logo Revolution Medicines, Inc.
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.
Employees
883
Date Price Change Volume
26-06-08 148.49 $ -0.50% 2,734,779
26-06-05 149.23 $ -4.15% 2,140,414
26-06-04 155.69 $ -0.19% 2,609,527
26-06-03 155.99 $ +3.09% 2,008,033
26-06-02 151.31 $ -7.56% 3,750,390
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
148.49USD
Average target price
186.33USD
Spread / Average Target
+25.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RVMD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW